Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
about
Epithelial cell dissemination and readhesion: analysis of factors contributing to metastasis formation in breast cancerUnderstanding and treating triple-negative breast cancerSqualene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II diseaseThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Approach to the Triple Negative Breast Cancer in New Drugs AreaThe role of preoperative systemic treatment in patients with breast cancerNeoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureTriple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-AnalysisCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerCancer Stem Cell Plasticity Drives Therapeutic ResistanceMolecular Imaging of Biomarkers in Breast CancerBiomarkers in triple negative breast cancer: A reviewThe fate of chemoresistance in triple negative breast cancer (TNBC)Revealing the Complexity of Breast Cancer by Next Generation SequencingTargeted Therapies in Triple-Negative Breast CancerThe role of taxanes in triple-negative breast cancer: literature reviewAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsTargeting triple-negative breast cancer: optimising therapeutic outcomesMicroRNAs and triple negative breast cancerEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyGenomic profiling in triple-negative breast cancerCancer-associated fibroblasts in digestive tumorsA new paradigm for mechanobiological mechanisms in tumor metastasisBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Systemic treatment strategies for triple-negative breast cancer.Neoadjuvant therapy in the treatment of breast cancerNovel therapeutic strategies for patients with triple-negative breast cancerA perspective on anti-EGFR therapies targeting triple-negative breast cancerMolecular subtypes and imaging phenotypes of breast cancer.Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trialsTriple-negative breast cancer: is there a treatment on the horizon?Role of positron emission tomography for the monitoring of response to therapy in breast cancerProtective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiationNovel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cellsEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerMolecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapyOpportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerTranslating neoadjuvant therapy into survival benefits: one size does not fit all.
P2860
Q24606925-06BE350D-2E80-48AF-97FD-8BF165D38A79Q24620957-EF670478-CB54-42B2-9F51-D9F0E1278D67Q24655384-0F641D83-799B-42FA-BFCD-DD3F5F26589AQ24657145-8DE30215-2D22-4BDA-B621-8FBB87C04B12Q26744054-5571C896-8DDE-4401-B412-F5DCE8255202Q26746034-3324CBD0-7297-439E-A040-1F8F92D761ABQ26751249-D04C5E8E-4448-4F8C-BADC-820648E712CFQ26753881-4F173133-F00B-4D19-93D9-4D4A0A69655DQ26764987-61473006-D48B-4F6E-A05A-D4AE86AAE8D9Q26770274-0982656F-60C9-47BC-B6C1-A2C1C6ED1AF1Q26772870-DBB8C096-FCAF-43D8-9F7E-03314E29228AQ26775094-7D1DA4DB-D5A8-46F6-B575-0B48CDC15071Q26775232-D98D3691-D5AB-43F1-ABDF-61E9CA2502A8Q26777395-1E74080A-56D5-4A41-B6A3-31E0CC547E2EQ26777736-41B77DDF-BEE8-4258-B3C1-E886D5F70881Q26798356-1BDF636D-710C-41BB-A7D0-CA52D0F0CB8EQ26798674-29F0AD33-090B-499A-9B6D-51DEFB4A4857Q26850892-0B8420F4-CB49-4051-BF74-2518557FBBF1Q26862716-4D821AAE-4A60-410C-946A-59D23C661739Q27011535-ED3A6CFA-A3CC-4CF2-A4F6-FF10B4A8E220Q27011658-4D4EA97F-FEE0-45C1-BAE7-3823CABB29A4Q27015775-6348329C-5946-47C1-AB43-1F71D27622B9Q27022816-2CA4CC0A-533F-411F-B1AB-122A0B5BB51AQ27024486-3508E4DE-FD8F-4FF0-B828-3EDB9C29972CQ27311085-7C4368BF-CB93-40E2-81AD-F881010CB971Q27691414-A401843E-5958-43C1-91A1-F474551A19BDQ27694514-104C0676-42AB-439E-AB80-7EB1A69074ADQ28067436-D5580F93-2167-4095-AC3C-8776FF7FD740Q28069867-5BF7BF4D-8CEB-4263-81B5-4DE88A4BDB53Q28069885-BC4F6FFA-DC2E-4F75-BB49-8FB2A564183CQ28072923-AE61C2B6-37D3-4E3D-8FD5-EA978020F8D2Q28077243-CC354A23-3C53-44F8-AF8B-3670A7244DC4Q28080621-984E0631-8FC1-445A-AEAD-E212B935FBB7Q28235715-B617040E-AAC1-4E17-9E60-E450DED364BCQ28259152-B97912AD-6D2D-49C9-A237-6EB93377CE22Q28372484-4969FB5E-7D6C-4485-926F-0274D716BEC8Q28535227-14DBC8CD-6037-4BDF-9471-4BDA1FC432E6Q29248325-F1D6A9C5-3813-4A0B-A071-40F778477392Q29616360-1458D02F-9667-48C3-9ED7-D4035C4B958FQ30251738-F00B94CD-DED3-448D-AEA0-EC889191E8CB
P2860
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Response to neoadjuvant therap ...... triple-negative breast cancer.
@en
Response to neoadjuvant therap ...... triple-negative breast cancer.
@nl
type
label
Response to neoadjuvant therap ...... triple-negative breast cancer.
@en
Response to neoadjuvant therap ...... triple-negative breast cancer.
@nl
prefLabel
Response to neoadjuvant therap ...... triple-negative breast cancer.
@en
Response to neoadjuvant therap ...... triple-negative breast cancer.
@nl
P2093
P356
P1476
Response to neoadjuvant therap ...... triple-negative breast cancer.
@en
P2093
Ana M Gonzalez-Angulo
Attila Tordai
Bryan Hennessy
Chafika Mazouni
Cornelia Liedtke
Fabrice André
Gabriel N Hortobagyi
Jaime A Mejia
Kenneth R Hess
Lajos Pusztai
P304
P356
10.1200/JCO.2007.14.4147
P407
P577
2008-02-04T00:00:00Z